Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Amyris Biotechnologies
So what: There was no news today, but earlier in the week Amyris announced a collaboration and joint development agreement with Switzerland-based Firmenich. Two analysts also initiated coverage on the company earlier in the week, with one "buy" rating and one "neutral" rating.
Now what: Investors seem to be a little late reacting on this one. Amyris looks to be on the right track, but the massive losses it is posting will keep me away from this stock. I would like to see the company at least getting closer to a profit before diving in, despite what analysts say.
Interested in more info on Amyris? Add it to your watchlist here by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.